Supplements to consider

Furthermore, female sexual arousal disorder is a heterogeneous condition whose underlying causes are difficult to diagnose and appropriate treatment requires a thorough sexual, psychological, and medical history along with specialist consultations. The clinician should pursue a global approach to the patient with sexual difficulties, while non-hormonal treatment such as phosphodiesterase type 5 inhibitors (ie, sildenafil citrate) should be kept as the last option. Keywords: phosphodiesterase type 5 inhibitors, female sexual arousal disorder (FSAD), sildenafil citrate In clinical practice, not only gynecologists but also generalists are often asked to solve specific questions about sexual diseases. According to recent estimates, sexual dysfunction has occurred in 40%–45% of women and 20%–30% of men at least once in their lifetime.1 For years, studies have focused mainly on erectile dysfunction while female sexual disorders (FSDs), although more frequent than male sexual disturbances, have been hardly considered.2 Even general practitioners are used to dealing with male sexual dysfunction and often prescribe easily available drugs such as sildenafil citrate (Viagra®).

The Clinically Proven Treatment for Low Sexual Desire

In fact, genital congestion and lubrication strictly depend on the hormonal balance (ie, arousal disorders during the menopausal transition) and require adequate vascular function and an efficient nerve transmission of mechanical stimuli.4 Thus, iatrogenic factors (eg, chronic antidepressant treatments, surgical procedures, radiotherapy of the pelvis), along with endocrine, vascular, and neurological disorders can cause female sexual dysfunction. However, a modern definition of FSDs should not focus only on genital phenomena without considering the psychological aspect of arousal. In fact, women very often relate arousal to the subjective feeling of been “sexually involved” more than to the physiological response to erotic stimuli (ie, vaginal lubrication and engorgement of sexual tissues such as nipples, vulva, clitoris, and vaginal walls). Thus, such factors as sexual inhibition, depression or anxiety, inadequate sexual stimulation, or interpersonal problems may impair women’s arousal. Moreover, FSADs are frequently associated with other FSDs concerning desire, orgasm, and pain.4 To sum up, Basson et al5 categorized FSAD into three main classes: subjective, genital, and combined (Table 1).

Can Any Supplement Help Women Climax?

In subjective FSAD, the woman’s emotional response to sexual stimuli is altered but the physical response still occurs, while genital phenomena are impaired in objective FSAD. However, in most cases, both factors contribute to FSAD (combined). In smooth muscle cells, nitric oxide activates the guanylate cyclase enzyme which converts guanosine triphosphate into cyclic guanosine monophosphate. This molecule promotes the relaxation of the smooth muscle cells, causes vasodilatation, and increases blood flow in genital organs. The engorgement of penile corpora cavernosa in men and clitoris and labia minora in women are the main modifications of genital organs during sexual arousal. On the contrary, women have begun to complain about sexual troubles only recently and have caught their doctors off-guard.

How should FSD be diagnosed and treated? A more thorough understanding of female sexual problems is needed to ensure appropriate clinical management of sexual difficulties.

The Diagnostic and Statistical Manual of Mental Disorder, Fifth Edition (DSM-V)2 defines FSDs as disturbances in the female sexual response cycle, resulting in marked distress and interpersonal difficulties.

In particular, female sexual arousal disorder (FSAD) belongs to the so-called “female sexual interest/arousal disorder” and is one of the most prevalent subcategories of FSDs.

• Female aphrodisiacs with tropical herbs.
• Libido boosters with vitamin complexes.
• Pills to reduce sexual anxiety.
• Natural solutions to improve intimacy.
• Aphrodisiac formulations for women.
• Herbal pills that increase sensitivity.

FSAD is traditionally defined as a persistent or recurrent inability to attain or maintain adequate lubrication and genital swelling until completion of sexual activity.3 Such a clinical condition may depend either on local or general factors.

6. Tribulus Terrestris (Puncture Vine)

Furthermore, the ultrafiltration of plasma through capillary vaginal vessels contributes to vaginal lubrication.6 Phosphodiesterase type 5 (PDE5) inhibitors (eg, sildenafil, tadalafil, vardenafil) physiologically enhance the production of guanosine monophosphate from cyclic guanosine monophosphate, thus contrasting the above-mentioned effects (Figure 1). According to emerging data, PDE5 super p force online is expressed in vaginal, clitoral, and labial smooth muscles. Thus, PDE5 inhibitors could be used as an easily available medical treatment for genital FSADs.7 Sildenafil citrate (Viagra), a PDE5 inhibitor, has been successfully used for the treatment of male erectile dysfunction since the late 1990s.8 The analogies between male and female physiological response to sexual stimuli have prompted studies over its efficacy in FSAD. However, there are presently very few data regarding the use of sildenafil in women and the results are still conflicting. In a randomized double-blind study, Berman et al administered sildenafil to 202 postmenopausal women with a primary diagnosis of FSAD and possibly associated secondary FSDs.

Comparison table

Patients randomly received 12 weeks of treatment with sildenafil citrate 50 mg or placebo. A significant improvement of arousal sensation, lubrication, and orgasm was reported in the study group affected by primary FSAD. On the contrary, women affected by different types of FSDs (eg, hypoactive sexual disorder, dyspareunia due to vaginal dryness) did not experience any significant improvement in desire, pain, or enjoyment.9 In all the studies confirming the positive results of sildenafil, the drug proved to be more effective in the genital subgroup. It can be speculated that sildenafil citrate only acts on the physical phenomena of arousal and does not completely respond to the complexity of FSAD. In fact, encouraging results were achieved in specific groups of patients affected by secondary FSADs (eg, diabetes mellitus, multiple sclerosis, chronic antidepressant users) in which the genital arousal disorder is clearly connected with a neurological or vascular injury.10–12 However, negative results are also reported in literature. In fact, genital congestion and lubrication strictly depend on the hormonal balance (ie, arousal disorders during the menopausal transition) and require adequate vascular function and an efficient nerve transmission of mechanical stimuli.4 Thus, iatrogenic factors (eg, chronic antidepressant treatments, surgical procedures, radiotherapy of the pelvis), along with endocrine, vascular, and neurological disorders can cause female sexual dysfunction. However, a modern definition of FSDs should not focus only on genital phenomena without considering the psychological aspect of arousal. In fact, women very often relate arousal to the subjective feeling of been “sexually involved” more than to the physiological response to erotic stimuli (ie, vaginal lubrication and engorgement of sexual tissues such as nipples, vulva, clitoris, and vaginal walls). Thus, such factors as sexual inhibition, depression or anxiety, inadequate sexual stimulation, or interpersonal problems may impair women’s arousal. Moreover, FSADs are frequently associated with other FSDs concerning desire, orgasm, and pain.4 To sum up, Basson et al5 categorized FSAD into three main classes: subjective, genital, and combined (Table 1). In subjective FSAD, the woman’s emotional response to sexual stimuli is altered but the physical response still occurs, while genital phenomena are impaired in objective FSAD. However, in most cases, both factors contribute to FSAD (combined). In smooth muscle cells, nitric oxide activates the guanylate cyclase enzyme which converts guanosine triphosphate into cyclic guanosine monophosphate. This molecule promotes the relaxation of the smooth muscle cells, causes vasodilatation, and increases blood flow in genital organs. The engorgement of penile corpora cavernosa in men and clitoris and labia minora in women are the main modifications of genital organs during sexual arousal. Furthermore, the ultrafiltration of plasma through capillary vaginal vessels contributes to vaginal lubrication.6 Phosphodiesterase type 5 (PDE5) inhibitors (eg, sildenafil, tadalafil, vardenafil) physiologically enhance the production of guanosine monophosphate from cyclic guanosine monophosphate, thus contrasting the above-mentioned effects (Figure 1). According to emerging data, PDE5 super p force online is expressed in vaginal, clitoral, and labial smooth muscles. Thus, PDE5 inhibitors could be used as an easily available medical treatment for genital FSADs.7 Sildenafil citrate (Viagra), a PDE5 inhibitor, has been successfully used for the treatment of male erectile dysfunction since the late 1990s.8 The analogies between male and female physiological response to sexual stimuli have prompted studies over its efficacy in FSAD. However, there are presently very few data regarding the use of sildenafil in women and the results are still conflicting.

• [Magnet Therapy Pills: Placebo pills claiming energetic benefits.]
• [Homeopathic Libido Pills: Highly diluted substances.]
• [Libigirl: Herbal supplement blend for women.]
• [VigorUp for Women: Contains tribulus and other herbs.]
• [HerSolution: Herbal supplement marketed for arousal.]

In a randomized double-blind study, Berman et al administered sildenafil to 202 postmenopausal women with a primary diagnosis of FSAD and possibly associated secondary FSDs. Patients randomly received 12 weeks of treatment with sildenafil citrate 50 mg or placebo.

Find out if treatment is right for you.

Furthermore, female sexual arousal disorder is a heterogeneous condition whose underlying causes are difficult to diagnose and appropriate treatment requires a thorough sexual, psychological, and medical history along with specialist consultations. The clinician should pursue a global approach to the patient with sexual difficulties, while non-hormonal treatment such as phosphodiesterase type 5 inhibitors (ie, sildenafil citrate) should be kept as the last option. Keywords: phosphodiesterase type 5 inhibitors, female sexual arousal disorder (FSAD), sildenafil citrate In clinical practice, not only gynecologists but also generalists are often asked to solve specific questions about sexual diseases. According to recent estimates, sexual dysfunction has occurred in 40%–45% of women and 20%–30% of men at least once in their lifetime.1 For years, studies have focused mainly on erectile dysfunction while female sexual disorders (FSDs), although more frequent than male sexual disturbances, have been hardly considered.2 Even general practitioners are used to dealing with male sexual dysfunction and often prescribe easily available drugs such as sildenafil citrate (Viagra®). On the contrary, women have begun to complain about sexual troubles only recently and have caught their doctors off-guard.

How quickly should I expect to see results from Sex Dust®?

How should FSD be diagnosed and treated? A more thorough understanding of female sexual problems is needed to ensure appropriate clinical management of sexual difficulties. The Diagnostic and Statistical Manual of Mental Disorder, Fifth Edition (DSM-V)2 defines FSDs as disturbances in the female sexual response cycle, resulting in marked distress and interpersonal difficulties. In particular, female sexual arousal disorder (FSAD) belongs to the so-called “female sexual interest/arousal disorder” and is one of the most prevalent subcategories of FSDs. FSAD is traditionally defined as a persistent or recurrent inability to attain or maintain adequate lubrication and genital swelling until completion of sexual activity.3 Such a clinical condition may depend either on local or general factors. A significant improvement of arousal sensation, lubrication, and orgasm was reported in the study group affected by primary FSAD. On the contrary, women affected by different types of FSDs (eg, hypoactive sexual disorder, dyspareunia due to vaginal dryness) did not experience any significant improvement in desire, pain, or enjoyment.9 In all the studies confirming the positive results of sildenafil, the drug proved to be more effective in the genital subgroup. It can be speculated that sildenafil citrate only acts on the physical phenomena of arousal and does not completely respond to the complexity of FSAD. In fact, encouraging results were achieved in specific groups of patients affected by secondary FSADs (eg, diabetes mellitus, multiple sclerosis, chronic antidepressant users) in which the genital arousal disorder is clearly connected with a neurological or vascular injury.10–12 However, negative results are also reported in literature. Firstly, women affected by FSADs do not benefit from sildenafil citrate as much as men with erectile dysfunction as a result of a lower concentration of PDE5 in vaginal and clitoral tissues than in penile corpora cavernosa.7 Secondly, a randomized double-blind study including both pre- and postmenopausal women did not show any success from sildenafil citrate treatment. In fact, no significant changes in physical response during sexual activity were reported in either group of women.13 It should also be considered that sildenafil citrate is not devoid of side effects. The most common adverse events reported in all studies were headache, flushing, nausea, rhinitis, and visual disturbances.14 In addition, sildenafil is strictly contraindicated in patients using oral or transdermal nitrates, as it dangerously potentiates the hypotensive effect of these drugs.8 Due to these major drawbacks as well as to the lack of conclusive results, non-hormonal treatments for FSAD have not been approved yet.

Natural Ways to Increase Libido

Firstly, women affected by FSADs do not benefit from sildenafil citrate as much as men with erectile dysfunction as a result of a lower concentration of PDE5 in vaginal and clitoral tissues than in penile corpora cavernosa.7 Secondly, a randomized double-blind study including both pre- and postmenopausal women did not show any success from sildenafil citrate treatment. In fact, no significant changes in physical response during sexual activity were reported in either group of women.13 It should also be considered that sildenafil citrate is not devoid of side effects. The most common adverse events reported in all studies were headache, flushing, nausea, rhinitis, and visual disturbances.14 In addition, sildenafil is strictly contraindicated in patients using oral or transdermal nitrates, as it dangerously potentiates the hypotensive effect of these drugs.8 Due to these major drawbacks as well as to the lack of conclusive results, non-hormonal treatments for FSAD have not been approved yet. Only a few studies have evaluated the role of other PDE5 inhibitors in FSADs. Van der Made et al examined the efficacy of vardenafil alone or combined with testosterone in 28 women affected by FSADs and/or hypoactive sexual desire disorder.

Reducing Stress And Enhancing Mood

The combination of testosterone and vardenafil caused an improvement in genital response (ie, vaginal pulse amplitude at vaginal photoplethysmography), especially in a group that initially had low attention for sexual cues.15 The efficacy of tadalafil was evaluated in 33 type 1 premenopausal diabetic women affected by sexual genital arousal disorder. A daily dose of tadalafil 5 mg treatment seemed to improve subjective sexual aspects. It was suggested that this treatment may be effective in improving clitoral blood flow as well as the clitoral functional system, consisting of smooth muscle cells and vascular spaces.16 There are a few things that a generalist should bear in mind when addressing a woman with FSAD. Firstly, which type of women may suffer from FASD? Especially postmenopausal patients in whom lubrication and swelling are physiologically impaired. Only a few studies have evaluated the role of other PDE5 inhibitors in FSADs. Van der Made et al examined the efficacy of vardenafil alone or combined with testosterone in 28 women affected by FSADs and/or hypoactive sexual desire disorder. The combination of testosterone and vardenafil caused an improvement in genital response (ie, vaginal pulse amplitude at vaginal photoplethysmography), especially in a group that initially had low attention for sexual cues.15 The efficacy of tadalafil was evaluated in 33 type 1 premenopausal diabetic women affected by sexual genital arousal disorder.

A daily dose of tadalafil 5 mg treatment seemed to improve subjective sexual aspects. It was suggested that this treatment may be effective in improving clitoral blood flow as well as the clitoral functional system, consisting of smooth muscle cells and vascular spaces.16 There are a few things that a generalist should bear in mind when addressing a woman with FSAD. Firstly, which type of women may suffer from FASD? Especially postmenopausal patients in whom lubrication and swelling are physiologically impaired. However, even psychological and cultural factors due to aging (ie, change in the familial structure, departure of the siblings, retirement) should be taken into account when addressing an elderly woman with sexual difficulties. In particular, the success of a treatment should be based on a detailed “couple interview.” In case of partnership involvement, the information has to provide the investigator with insight into the level of sexual function and the sexual preference of both partners; otherwise, all therapeutic steps could remain ineffective.17 Secondly, the “blue miracle pill,” although easily available, is not always the right cure.

From Mayo Clinic to your inbox

However, even psychological and cultural factors due to aging (ie, change in the familial structure, departure of the siblings, retirement) should be taken into account when addressing an elderly woman with sexual difficulties. In particular, the success of a treatment should be based on a detailed “couple interview.” In case of partnership involvement, the information has to provide the investigator with insight into the level of sexual function and the sexual preference of both partners; otherwise, all therapeutic steps could remain ineffective.17 Secondly, the “blue miracle pill,” although easily available, is not always the right cure. In fact FSAD, as a complex disease, may depend on several underlying medical conditions that need to be appropriately diagnosed and treated. Therefore, the general practitioner should immediately exclude chronic antidepressant treatments, surgical procedures, or radiotherapy of the pelvis and ascertain the presence of possible systemic pathologies such as endocrine, vascular, and neurological disorders. In these cases, the patient should be referred to the appropriate specialist (eg, endocrinologist, surgeon, neurologist).

23 best supplements for female libido

Nevertheless, in the absence of any evident systemic pathology, a generalist should propose both a gynecological and psychological consultation. In fact, objective FSAD (reduced genital physical response to sexual stimuli) may be a sign of various gynecological disorders. As reduced lubrication can cause pain during sexual intercourse, it should be differentiated from other possible causes of dyspareunia such as endometriosis, vulvar vestibulitis syndrome, and recurrent genital or urinary infections. On the contrary, preserved physical response with reduced emotional involvement probably indicates a psychological disturbance that can benefit from cognitive behavioral therapy or traditional sex therapy. In fact FSAD, as a complex disease, may depend on several underlying medical conditions that need to be appropriately diagnosed and treated. Therefore, the general practitioner should immediately exclude chronic antidepressant treatments, surgical procedures, or radiotherapy of the pelvis and ascertain the presence of possible systemic pathologies such as endocrine, vascular, and neurological disorders. In these cases, the patient should be referred to the appropriate specialist (eg, endocrinologist, surgeon, neurologist). Nevertheless, in the absence of any evident systemic pathology, a generalist should propose both a gynecological and psychological consultation. In fact, objective FSAD (reduced genital physical response to sexual stimuli) may be a sign of various gynecological disorders.

• [Nitric Oxide Boosters: Often contain arginine and citrulline.]
• [L-Citrulline: Converts to arginine, may support blood flow.]
• [Beetroot Powder: Natural source of nitrates for circulation.]
• [Pomegranate Extract: Antioxidant for vascular health.]
• [Dark Chocolate: Contains flavonoids, mood and circulation.]

As reduced lubrication can cause pain during sexual intercourse, it should be differentiated from other possible causes of dyspareunia such as endometriosis, vulvar vestibulitis syndrome, and recurrent genital or urinary infections. On the contrary, preserved physical response with reduced emotional involvement probably indicates a psychological disturbance that can benefit from cognitive behavioral therapy or traditional sex therapy.

Unser Haus